Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite ...

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price objective reduced by Barclays from $28.00 to $26.00 in ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

Check the time stamp on this data. Updated AI-Generated Signals for Teva Pharmaceutical Industries Limited American ...

SaverOne 2014 (SVRE) announced the award of a new contract with Teva Pharmaceutical (TEVA), to install the SaverOne System across its entire ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...